Overview

Gender

female

Mary co-founded KaNDy Therapeutics in 2017 as a spin out from NeRRe Therapeutics. KaNDy was formed to ensure a single-minded focus in developing NT-814 as a novel and breakthrough treatment for symptoms of the menopause.

Mary has held a range of senior leadership roles in the pharmaceutical industry having spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. She was a founding member of the executive team of ViiV Healthcare (the independent, HIV company that combines the HIV expertise of GSK, Pfizer Inc. and Shionogi) where she led, revitalised and grew the business throughout Europe.

Mary was also previously Senior Vice President and Global Franchise Head at GSK. Mary also currently serves as CEO of NeRRe and is a non-executive independent director at Galapagos NV.

Mary gained a PhD in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation, Detroit and has an MBA from the University of Kingston.